Cagrilintide
A long-acting amylin analog — the 'Cagri' half of CagriSema.
Overview
Cagrilintide is a once-weekly version of amylin, a hormone released with insulin that signals fullness. Novo Nordisk developed it mainly to pair with semaglutide as CagriSema. On its own it causes moderate weight loss; the combination is under FDA review, with a decision expected around late 2026. Cagrilintide alone is not approved anywhere.
How it works
A 37-amino-acid modified amylin analog with a C18 fatty diacid for a long half-life. It activates amylin and calcitonin receptors in the brain, increasing fullness and slowing stomach emptying — a different pathway from GLP-1, which is why the two are combined.
Evidence
4/5
Phase 2 RCT of cagrilintide alone and large phase 3 RCTs (REDEFINE) with a cagrilintide-only arm. Not approved as a standalone drug.
Half-life
About 7–8 days (once-weekly dosing)
Known as
NN9838, AM833, Cagri
Compound facts
- Type
- Long-acting acylated amylin analog
- Amino acids
- 37 (modified amylin sequence)
- Molecular weight
- 4,409 g/mol
- CAS Number
- 1415456-99-3
- Molecular formula
- C₁₉₄H₃₁₂N₅₄O₅₉S₂
- Modification
- C18 fatty diacid acylation
Reported benefits
Weight loss on its own
Phase 2 (Lancet 2021): −10.8% at 26 weeks on 4.5 mg vs −3.0% on placebo.
Monotherapy arm in phase 3
REDEFINE 1: cagrilintide 2.4 mg alone gave about −11.5% at 68 weeks (vs −3.0% on placebo).
Adds to semaglutide
REDEFINE 1: CagriSema about −20.4% vs −14.9% for semaglutide alone over 68 weeks (−22.7% in people who stayed on treatment).
“Anecdotal” means reported by users, not shown in controlled trials.
Community-reported regimens
Not recommendations. These are commonly cited ranges, shown so you can see what real-world use looks like.
| Plan | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
| Trial-style start REDEFINE titrated to 2.4 mg over about 16 weeks (0.25 → 0.5 → 1 → 1.7 → 2.4 mg). Community users often copy this schedule. | 250 mcg | Once weekly | 4 weeks, then step up | Subcutaneous |
| Phase 3 target dose The dose used in CagriSema and the REDEFINE monotherapy arm. | 2400 mcg | Once weekly | Trials ran 68 weeks | Subcutaneous |
Reconstitution calculator
Set up for Cagrilintide. Switch peptide or vial size any time.
1Mix
Add 2 mL water for 5 mg/mL
2Draw
Draw to 5 units = 0.05 mL = 250 mcg
Drag the plunger to set your dose.
3Inject
Next site
Right belly, upper
Tap a site after you inject to keep a rotation.
Pinch the skin, stay 2 in. from the navel, then into a sharps bin.
- Doses per vial
- 40
- Vial lasts
- 280 days
- Good once mixed
- ~28 days
- Syringe
- 30-unit, 0.3 mL
The vial outlasts its ~28-day shelf life once mixed. A smaller vial wastes less.
Math only: concentration (mg/mL) = vial mg ÷ mL of water; units = dose (mg) ÷ concentration × 100. Always double-check against your own vial label and a clinician. This tool does not recommend a dose.
Reconstitution
Diluent: Bacteriostatic water (0.9% benzyl alcohol) — allows multiple draws from one vial.
- Wipe both vial tops with an alcohol swab and let dry.
- Draw the diluent, then inject it slowly down the inside wall of the vial — never straight onto the powder.
- Swirl gently or let it sit; do not shake. Foam can damage peptides.
- Solution should be clear. Cloudy, stringy or discolored = discard.
- Do not mix cagrilintide and semaglutide in the same vial; separate vials and separate draws.
- Common mix: 10 mg + 4 mL = 2.5 mg/mL (250 mcg = 10 units).
Storage
Powder
Freezer / fridge
Keep sealed vial in the freezer (−20 °C) for long-term storage; fridge (2–8 °C) is fine for a few weeks. Keep dry and out of light.
After mixing
~28 days
Refrigerate at 2–8 °C. Never freeze after mixing. Keep upright, capped, and out of light.
Travel
Keep cool
Short trips at room temperature are generally fine for powder; keep mixed vials cold.
- Protect from light.
Side effects & cautions
Reported side effects
- Nausea, vomiting, constipation, diarrhea
- Reduced appetite
- Fatigue
- Injection-site reactions
Cautions
- Not a GLP-1 drug, but GI side effects add up if combined with one — titrate slowly.
- Gallbladder problems and low blood sugar (with insulin or sulfonylureas) are possible with weight-loss drugs of this kind.
- No data in pregnancy or breastfeeding.
- Investigational as a single agent; long-term safety is not established.
FDA & international status
Not FDA-approved
Cagrilintide alone is investigational. Novo Nordisk filed CagriSema (cagrilintide + semaglutide) with the FDA in December 2025; a decision is expected around Q4 2026. Research vials are unregulated and are not CagriSema.
Regulations change often — verify with the FDA, EMA, MHRA, Health Canada, TGA and WADA before acting.
Often paired with
SemaglutideThis is the CagriSema combination, tested in phase 3. The studied product was a fixed-dose co-formulation at 2.4 mg + 2.4 mg.
Where to buy
| Size | Price | Per mg | Stock | Latest COA |
|---|---|---|---|---|
| 10 mg | $69.99 | $7.00 | In stock | 99.84% pure, lot CAG0002 ILS Labs, tested 2026-07-30 |
Amino Club list prices as of 2026-10-07, before promo codes. Multi-buy: 2+ units 5% off, 3+ units 7.5% off, 10+ units 40% off. Prices change; confirm on the product page. Mixing? Their bacteriostatic water is Amino H2O from $19.99.
Cagrilintide at Amino Club
Check sizes, current price and the certificate of analysis (COA) on the product page. Sold for in-vitro research only.
Get Cagrilintide alerts
An email when its price drops, a sale starts, or its FDA or WADA status changes.
Affiliate link: we may earn a commission at no cost to you. Disclosure
- Look for a batch-specific COA with HPLC purity (≥98%) and mass-spec identity.
- Typical vial sizes: 10 mg.
FAQ
Is cagrilintide a GLP-1?
No. It mimics amylin, a different fullness hormone. That's why it adds to semaglutide rather than duplicating it.
Is it as strong as semaglutide alone?
No. On its own it gave roughly 11–12% weight loss in trials, versus about 16% for semaglutide 2.4 mg in the same study.
Can I combine it with tirzepatide or retatrutide?
There is no published trial of those combinations. The only well-studied pairing is with semaglutide.